Fecal microbiota transplants improve cognitive impairment caused by severe liver disease

April 21, 2017, European Association for the Study of the Liver

A study presented today found that faecal transplantation of bacteria from one healthy donor into patients that suffer from hepatic encephalopathy (decline in brain function due to severe liver disease), is safe and improves cognitive function compared with standard of care treatment for the condition. Presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, the study results also demonstrated that the number of hospitalisations following faecal transplantation plus antibiotics was two, compared to the standard of care arm (lactulose and rifaximin), which was 11 (IQR 83 days). Specifically, there was a significant reduction in hospitalisations due to recurrent hepatic encephalopathy (six in the standard of care and none in the faecal transplant arm).

In the study, faecal plus antibiotic was well tolerated without any serious side effects. Furthermore, it was found that the faecal transplant plus antibiotic therapy restored antibiotic-associated changes in the body's bacterial composition.

"Hepatic encephalopathy is a serious condition and a leading cause of re-admission to hospital due to recurrence, despite standard of care treatment," said Dr Jasmohan Bajaj, Virginia Commonwealth University, Richmond, United States of America, and lead author of the study. "The results from this study demonstrate that in patients with , a faecal transplant improves more than standard of care as well as reducing the number of hospital admissions, including those for recurrent hepatic encephalopathy. Faecal transplantation is an innovative and promising approach to treat this condition, and we look forward to more studies being conducted to confirm our results."

Researchers randomised 20 men with cirrhosis who experienced recurrent episodes of hepatic encephalopathy prior to the start of the study, to treatment with lactulose and rifaximin (standard of care treatment), or, broad spectrum antibiotics for five days plus a single faecal transplant from a healthy donor along with continuing the standard of care. The transplant was given as an enema. Patients were followed for up to 150 days after randomisation.

There was significant cognitive improvement in the faecal transplant group on the Psychometric Hepatic Encephalopathy Score (PHES) and the Stroop App (another test of cognitive dysfunction) as compared to the standard of care group. The Model for End Stage Liver Disease (MELD) score significantly increased following treatment with antibiotics (delta 1.7, p<0.001) but returned to baseline following the faecal transplant (delta -0.2, p=0.5, day 20). Faecal transplant also increased beneficial strains of bacteria, including Bifidobacteriaceae and Lactobacillaceae. In the standard of care arm, there were no significant microbiota, metabolomics, cognitive or MELD changes seen.

Overall, one patient in the faecal transplant group had decreased cognitive function, however he had higher baseline Proteobacteria, (a group of bacteria that includes a wide variety of pathogens, such as Escherichia, Salmonella, Vibrio, and Helicobacter), which did not respond to the faecal transplant.

Hepatic encephalopathy occurs when the liver cannot remove certain toxins and chemicals, such as ammonia, from the blood.1 These toxins and chemicals then build up and enter the brain.1 Hepatic encephalopathy is one of the major complications of cirrhosis (scarring of the liver), and a leading cause of hospital re-admission due to its recurrence, despite treatment.1 It can occur suddenly in people with acute liver failure, but is seen more often in those with chronic liver disease.1 Symptoms of hepatic encephalopathy include mild confusion, forgetfulness, poor concentration and personality or mood changes, but can progress to extreme anxiety, seizures, severe confusion, jumbled and slurred speech and slow movement.1 The first step in treatment is to identify and treat any factors that cause hepatic encephalopathy.2 Once the episode has resolved, further treatment aims to reduce the production and absorption of toxins, such as ammonia.1 Generally, there are two types of medication used to reduce the likelihood of another hepatic encephalopathy episode - lactulose and rifaximin.2 However, it remains a leading cause of hospitalisations and re-hospitalisations in cirrhotic patients, despite the use of the above-mentioned standard of care treatment.

"This is the first randomised trial to show that faecal transplantation may be of benefit to patients with hepatic encephalopathy. The encouraging findings open new avenues of research to determine how to best manipulate the gut microbiota in patients with hepatic . They also show proof-of-concept for the likely beneficial impact of such interventions, adding to what is already known for non-absorbable like rifaximin," said Prof Tom Karlsen, Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, Norway and EASL Vice-Secretary.

Explore further: Probiotics prevent deadly complications of liver disease

More information: Abstract: Fecal Microbiota Transplant Using a Precision Medicine Approach is Safe, Associated with Lower Hospitalization Risk and Improved Cognitive Function in Recurrent Hepatic Encephalopathy (PS085), The International Liver Congress 2017.

References:

1 British Liver Trust. Hepatic encephalopathy (HE). Available from: www.britishlivertrust.org.uk/l … atic-encephalopathy/. Last accessed: April 2017.

2 Vilstrup H, Amodio P, Bajaj J., et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology. 61(3): 642 - 659.

Related Stories

Probiotics prevent deadly complications of liver disease

June 6, 2014
Probiotics are effective in preventing hepatic encephalopathy in patients with cirrhosis of the liver, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American ...

Glycerol phenylbutyrate reduces hepatic encephalopathy events

February 25, 2014
Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to reduce hepatic encephalopathy ...

The healing effect of faecal microbiota transplantation lasts for long

October 11, 2016
Researchers in the University of Helsinki and Helsinki University Hospital have studied in detail the intestinal microbiota of 14 patients treated with a faecal microbiota transplant. The patients suffered from recurrent ...

Smartphone app found to be valid tool in screening for minimal hepatic encephalopathy

September 18, 2013
A smartphone app can quickly screen for cognitive dysfunction often found in patients with cirrhosis, according to a new Virginia Commonwealth University study. The cognitive dysfunction, known as minimal hepatic encephalopathy ...

Long-term antibiotic prophylaxis reduces mortality in people with advanced liver disease

April 20, 2017
A multicentre, randomised, controlled study presented today found that long-term oral antibiotic therapy with norfloxacin improved the prognosis of people with life-threatening advanced liver disease. The study, presented ...

Recommended for you

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.

Cell-free DNA profiling informative way to monitor urinary tract infections

June 20, 2018
Using shotgun DNA sequencing, Cornell University researchers have demonstrated a new method for monitoring urinary tract infections (UTIs) that surpasses traditional methods in providing valuable information about the dynamics ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.